Advanced Search

2023 Vol. 5, No. 23

Preplanned Studies
Periconceptional Folic Acid Only Versus Multiple Micronutrients Containing Folic Acid and Association with Gestational Diabetes Mellitus — Beijing Municipality, China, 2017–2021
Shuangbo Xia, Yushan Du, Ziyang Ren, Jinjuan Zhang, Suhong Gao, Jiamei Wang, Zhiwen Li, Xiaohong Liu, Jufen Liu
2023, 5(23): 505-510. doi: 10.46234/ccdcw2023.095
Abstract(2462) HTML (122) PDF 310KB(16)
Abstract:
What is already known about this topic?

Inconsistent results have been reported on the association between periconceptional folic acid only (FAO) or multiple micronutrients containing folic acid (MMFA) supplementation and the risk of gestational diabetes mellitus (GDM) in previous research.

What is added by this report?

In a prospective cohort study conducted among pregnant women in Haidian District, Beijing Municipality, it was observed that those who took MMFA demonstrated a higher likelihood of developing GDM in comparison to those who consumed FAO periconceptionally. Interestingly, the increased risk for GDM in pregnant women supplemented with MMFA compared to FAO was primarily due to changes in fasting plasma glucose.

What are the implications for public health practice?

It is highly recommended that women prioritize the use of FAO in order to yield potential benefits in the prevention of GDM.

A Comparison of Clinical Characteristics of Infections with SARS-CoV-2 Omicron Subvariants BF.7.14 and BA.5.2.48 — China, October–December 2022
Da Huo, Tong Yu, Ying Shen, Yang Pan, Fu Li, Shujuan Cui, Bing Lyu, Zhichao Liang, Daitao Zhang, Peng Yang, Quanyi Wang, Yue Sun, Zhaomin Feng
2023, 5(23): 511-515. doi: 10.46234/ccdcw2023.096
Abstract(3126) HTML (117) PDF 257KB(20)
Abstract:
What is already known about this topic?

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, the clinical manifestations resulting from different SARS-CoV-2 variants may demonstrate significant variation.

What is added by this report?

We conducted a comparative analysis of the clinical features associated with SARS-CoV-2 Omicron subvariants BF.7.14 and BA.5.2.48 infections. The results of our study indicate that there are no substantial differences in clinical manifestations, duration of illness, healthcare-seeking behaviors, or treatment between these two subvariants.

What are the implications for public health practice?

Timely identification of alterations in the clinical spectrum is crucial for researchers and healthcare practitioners in order to enhance their comprehension of clinical manifestations, as well as the progression of SARS-CoV-2. Furthermore, this information is beneficial for policymakers in the process of revising and implementing appropriate countermeasures.

Perspectives